Digitalis therapy for patients in clinical heart failure.
about
MicroRNA and Heart FailureSynergy of Omeprazole and Praziquantel In Vitro Treatment against Schistosoma mansoni Adult WormsEffectiveness of digoxin in reducing one-year mortality in chronic heart failure in the Digitalis Investigation Group trial.Role of mitochondrial dysfunction in cardiac glycoside toxicityHuman breast tumor cells are more resistant to cardiac glycoside toxicity than non-tumorigenic breast cells.Inhibiting Na+/K+ ATPase can impair mitochondrial energetics and induce abnormal Ca2+ cycling and automaticity in guinea pig cardiomyocytes.Effects of digoxin at low serum concentrations on mortality and hospitalization in heart failure: a propensity-matched study of the DIG trialEffects of discontinuation of digoxin versus continuation at low serum digoxin concentrations in chronic heart failure.You can do more to slow the progression of heart failure.Na+/K+-ATPase and cancer.Activation of Na+/K+-ATPase attenuates high glucose-induced H9c2 cell apoptosis via suppressing ROS accumulation and MAPKs activities by DRm217.An evidence-based review of recent advances in therapy for heart failure with reduced ejection fraction (HFrEF).The synthesis of cardenolide and bufadienolide aglycones, and related steroids bearing a heterocyclic subunit.Evaluation of the antihypertensive activity and alpha adrenergic receptor interaction of cleistanthins A and B.Activation of Na+-K+-ATPase with DRm217 attenuates oxidative stress-induced myocardial cell injury via closing Na+-K+-ATPase/Src/Ros amplifier.Examining risk factor goal attainment and adherence to treatment among US heart failure patients: the National Health and Nutrition Examination Survey 2007-2010.
P2860
Q26750638-2F74BCCB-3507-4FC4-8F55-53F18EA272CBQ28548401-8A668EC0-1C15-4EB1-98BF-7FDDC911A996Q33978533-A4284CCD-2D28-48EE-B520-2914D6965B86Q34172696-8F0F641B-1E8C-49BC-BE08-22DFE7C6CF8AQ35071149-00F195DA-AFDA-40A7-82A3-DBCBA4D7B175Q35145345-48884679-B16C-4265-B571-3B42A168DC3BQ36776095-CDE8F908-477F-41D8-9156-E3BD1CC1E1E7Q37199757-FF5B9A0A-3C78-488C-A92C-015BCB809332Q37216146-52633464-3B6C-4F95-B4D4-1FA368382E8BQ38162901-B7A4401C-920D-48B1-995C-2B293824C020Q38750004-981D7F25-09D0-44F0-A348-5908903E8E47Q38973132-3F1F8508-EF71-486D-A8C2-1FAEE7BB15FBQ39221272-21C91CB8-6A6D-4459-95A4-2BED98DE4B22Q42112521-2011B174-3F2D-4654-B02B-41B944BF1EF7Q46420697-EB2AB261-F34D-4472-B58D-0C20F0038732Q46973488-9B33A390-20C2-46CB-BBD2-D66BCCBB4629
P2860
Digitalis therapy for patients in clinical heart failure.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Digitalis therapy for patients in clinical heart failure.
@ast
Digitalis therapy for patients in clinical heart failure.
@en
type
label
Digitalis therapy for patients in clinical heart failure.
@ast
Digitalis therapy for patients in clinical heart failure.
@en
prefLabel
Digitalis therapy for patients in clinical heart failure.
@ast
Digitalis therapy for patients in clinical heart failure.
@en
P1433
P1476
Digitalis therapy for patients in clinical heart failure.
@en
P2093
Shahbudin H Rahimtoola
P304
P356
10.1161/01.CIR.0000132477.32438.03
P407
P577
2004-06-01T00:00:00Z